Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 2208 results found since Jan 2013.
Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
CONCLUSION: Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.PMID:37700573 | DOI:10.1177/10600280231197459
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Natalie Mausey Zachery Halford Source Type: research
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial using real-world data
This study replicated the atezolizumab and docetaxel arms of the OAK trial using RWD and compared progression-free survival (PFS) outcomes derived from abstracted physician's notes in RWD (rwPFS) against PFS outcomes derived from the clinical trial (ctPFS). Atezolizumab and docetaxel arms of the phase III OAK RCT (NCT02008227) were replicated in a US nationwide real-world database using selected OAK inclusion/exclusion criteria and propensity score-based adjustment for baseline prognostic variables. Concordance of outcomes was assessed using Kaplan-Meier (KM) medians and hazard ratios (HRs). The RWD cohorts comprised 133 a...
Source: Clinical Pharmacology and Therapeutics - September 11, 2023 Category: Drugs & Pharmacology Authors: Shivani K Mhatre Robson J M Machado Thanh G N Ton Huong Trinh Julien Mazieres Achim Rittmeyer Michael T Bretscher Source Type: research
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
CONCLUSIONS: In patients with recurrence after BCG therapy, sequential intravesical gem/doce is an effective and well-tolerated alternative to early cystectomy. Patients with BCG relapsing disease are more likely to respond to additional intravesical gem/doce. Further investigation with a prospective trial is imperative.PMID:37690933 | DOI:10.1016/j.urolonc.2023.06.018
Source: Urologic Oncology - September 10, 2023 Category: Urology & Nephrology Authors: Kendrick Yim Kevin Melnick Sarah L Mott Filipe L F Carvalho Affan Zafar Timothy N Clinton Matthew Mossanen Graeme S Steele Michelle Hirsch Natalie Rizzo Chin-Lee Wu Kent W Mouw Matthew Wszolek Keyan Salari Adam Feldman Adam S Kibel Michael A O'Donnell Mar Source Type: research
Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study
CONCLUSIONS: The dexamethasone-based mouthwash safely reduced stomatitis incidence and severity in patients receiving chemotherapy for early breast cancer. Phase 3 clinical trials are warranted for validating our results.PMID:37689451 | DOI:10.1016/j.jebdp.2023.101896
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Sayaka Kuba Shigeto Maeda Kenichiro Shibata Sakiko Soutome Kosho Yamanouchi Megumi Matsumoto Aya Tanaka Michi Morita Toshiko Hatachi Ryota Otsubo Hiroshi Yano Yumiko Kawashita Shuntaro Sato Hideki Taniguchi Kengo Kanetaka Masahiro Umeda Takeshi Nagayasu S Source Type: research
The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases
CONCLUSIONS: Brain metastases are an unfavorable prognostic factor in prostate cancer. The therapeutic options developed in recent years allow the improvement of survival.PMID:37685646 | DOI:10.3390/jcm12175579
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Roxana-Andreea Rahnea-Nita Laura-Florentina Rebegea Alexandru Nechifor Cristian Mare ș Radu-Valeriu Toma Alexandru-Rares Stoian Anda-Natalia Ciuhu Liliana-Florina Andronache Georgiana Bianca Constantin Gabriela Rahnea-Nita Source Type: research
Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma
CONCLUSION: The RMM-I molecular subtype constituted the novel molecular characteristic subtype of LUAD, which complemented the existing pathological typing. More refined and accurate molecular subtypes provide help to reveal the mechanism of LUAD development. In addition, the RMM-I score offers a reliable tool for accurate prognosis of LUAD.PMID:37680151 | DOI:10.2174/0929867331666230901110629
Source: Current Medicinal Chemistry - September 8, 2023 Category: Chemistry Authors: Jiajing Wang Jianfeng Shu Source Type: research
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma
CONCLUSIONS: After median follow-up of approximately 2 years, enfortumab vedotin maintained clinically meaningful overall survival benefit versus chemotherapy, consistent with findings from the EV-301 primary analysis; PFS and overall response benefit remained consistent. Adverse events were manageable; no new safety signals were observed.PMID:37678672 | DOI:10.1016/j.annonc.2023.08.016
Source: Ann Oncol - September 7, 2023 Category: Cancer & Oncology Authors: J E Rosenberg T Powles G P Sonpavde Y Loriot I Duran J-L Lee N Matsubara C Vulsteke D Castellano R Mamtani C Wu M Matsangou M Campbell D P Petrylak Source Type: research
